Generic placeholder image

Current Pharmaceutical Analysis

Author(s): Persia Behbahani, Nahid Ghasemi, Mahnaz Qomi* and Kambiz Tahvildari

DOI: 10.2174/1573412915666190523114036

DownloadDownload PDF Flyer Cite As
Trace Determination of Tamoxifen using Optimized Solvent Bar Microextraction and HPLC-UV

Page: [1068 - 1073] Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Background: Tamoxifen (Soltamox) is an antineoplastic agent and an estrogen receptor antagonist used to treat breast cancer, but have severe side effects such as hot flashes, vaginal discharge, etc. Dose monitoring is a necessity for optimum treatment, to prevent severe adverse effects.

Methods: In this study, the solvent bar microextraction method (SBME) was used for preconcentration and microextraction coupled with High-performance liquid chromatography-ultraviolet (HPLC-UV) analysis of tamoxifen.

Results: The limit of detection and limit of quantification were 13.3 and 40 μgL-1, respectively. The linear range was between 40 and 10000 μgL-1 with a correlation coefficient of 0.999. The enrichment factor was 169 and the relative standard deviation within-day and between-day were 3.6 and 4.0, respectively.

Conclusion: The use of sensitive SBME method coupled with HPLC-UV analysis for detection of tamoxifen at trace level proved to be successful, offering a desirable preconcentration factor, and a costeffective and green set-up for determining its rate of elimination from cancer patients and wastewater.

Keywords: Tamoxifen, solvent bar microextraction, HPLC-UV, chemometrics, real sample, antineoplastic agent.

Graphical Abstract

[1]
Goetz, M.P.; Kamal, A.; Ames, M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther., 2008, 83(1), 160-166.
[http://dx.doi.org/10.1038/sj.clpt.6100367] [PMID: 17882159]
[2]
Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet, 2005, 365(9453), 60-62.
[http://dx.doi.org/10.1016/S0140-6736(04)17666-6] [PMID: 15639680]
[3]
Wickramage, I.; Tennekoon, K.H.; Ariyaratne, M.A.Y.; Hewage, A.S.; Sundralingam, T. CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study. Breast Cancer (Dove Med. Press), 2017, 9, 111-120.
[http://dx.doi.org/10.2147/BCTT.S126557] [PMID: 28293118]
[4]
Zhu, Y. B.; Zhang, Q.; Zou, J. J.; Yu, C. X.; Xiao, D. W. Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study Journal of pharmaceutic biomed anal, 2008, 46(2), 349.
[5]
Esteve-Romero, J.; Ochoa-Aranda, E.; Bose, D.; Rambla-Alegre, M.; Peris-Vicente, J.; Martinavarro-Domínguez, A. Tamoxifen monitoring studies in breast cancer patients by micellar liquid chromatography. Anal. Bioanal. Chem., 2010, 397(4), 1557-1561.
[http://dx.doi.org/10.1007/s00216-010-3695-7] [PMID: 20422162]
[6]
Thang, L.Y.; Breadmore, M.C.; See, H.H. Electrokinetic supercharging in nonaqueous capillary electrophoresis for online preconcentration and determination of tamoxifen and its metabolites in human plasma. J. Chromatogr. A, 2016, 1461, 185-191.
[http://dx.doi.org/10.1016/j.chroma.2016.07.067] [PMID: 27485148]
[7]
Heydari, E.; Raoof, J.B.; Ojani, R.; Bagheryan, Z. SiO2 nanoparticles modified CPE as a biosensor for determination of i-motif DNA/Tamoxifen interaction. Int. J. Biol. Macromol., 2016, 89, 421-427.
[http://dx.doi.org/10.1016/j.ijbiomac.2016.05.001] [PMID: 27151665]
[8]
Lee, J.; Lee, H.K.; Rasmussen, K.E.; Pedersen-Bjergaard, S. Environmental and bioanalytical applications of hollow fiber membrane liquid-phase microextraction: a review. Anal. Chim. Acta, 2008, 624(2), 253-268.
[http://dx.doi.org/10.1016/j.aca.2008.06.050] [PMID: 18706332]
[9]
Jiang, X.; Lee, H.K. Solvent bar microextraction. Anal. Chem., 2004, 76(18), 5591-5596.
[http://dx.doi.org/10.1021/ac040069f] [PMID: 15362925]
[10]
Farshad, S.; Qomi, M.; Gholghasemi, M. Preconcentration and determination of cabergoline using the green practical solvent bar liquid phase microextraction technique in biological fluids. Curr. Pharmaceutic. Anal., 2018, 14(5), 437.
[http://dx.doi.org/10.2174/1573412913666170608095417]
[11]
Gerivani, Z.; Ghasemi, N.; Qomi, M.; Abdollahi, M.; Ma-lekirad, A.A. Optimization of extraction and pre-concentration of rizatriptan in biological samples using solvent bar and chemometrics Design. Curr. Pharmaceutic. Anal., 2018, 14(5), 450.
[http://dx.doi.org/10.2174/1573412913666170613091314]
[12]
Miraee, S.N.; Qomi, M.; Shamshiri, F.; Raoufi, P. Hollow-fiber liquid-phase microextraction followed by high performance liquid chromatography for the determination of trace amounts of methylphenidate hydrochloride in biological fluids. Biomed. Pharmacol. J., 2014, 7(2), 715.
[http://dx.doi.org/10.13005/bpj/546]
[13]
Lee, K.H.; Ward, B.A.; Desta, Z.; Flockhart, D.A.; Jones, D.R. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2003, 791(1-2), 245-253.
[http://dx.doi.org/10.1016/S1570-0232(03)00218-6] [PMID: 12798184]